Alx Financial Statements From 2010 to 2026

ALXO Stock  USD 1.57  0.20  14.60%   
Alx Oncology's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Alx Oncology's valuation are provided below:
Gross Profit
107 K
Market Capitalization
85.1 M
Enterprise Value Revenue
4.3 K
Earnings Share
(2.01)
Quarterly Revenue Growth
(1.00)
We have found one hundred twenty available fundamental signals for Alx Oncology Holdings, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to validate Alx Oncology's prevailing fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 30th of January 2026, Market Cap is likely to drop to about 95.2 M. In addition to that, Enterprise Value is likely to drop to about 94.5 M

Alx Oncology Total Revenue

0.0

Check Alx Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Alx Oncology's main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 9.2 M or Depreciation And Amortization of 1.1 M, as well as many indicators such as Price To Sales Ratio of 2.7 K, Dividend Yield of 0.0 or PTB Ratio of 0.72. Alx financial statements analysis is a perfect complement when working with Alx Oncology Valuation or Volatility modules.
  
Build AI portfolio with Alx Stock
Check out the analysis of Alx Oncology Correlation against competitors.

Alx Oncology Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets241.2 M169.9 M119.7 M
Slightly volatile
Other Current Liabilities11.9 M13.4 M6.5 M
Slightly volatile
Total Current Liabilities17.5 M21.3 M9.7 M
Slightly volatile
Other Liabilities57.9 K61 K229 K
Very volatile
Property Plant And Equipment Net5.6 M11.1 M3.5 M
Slightly volatile
Accounts Payable4.6 M5.2 M2.6 M
Slightly volatile
Cash15 M15.8 M58.9 M
Pretty Stable
Non Current Assets Total18.5 M15.4 M9.4 M
Slightly volatile
Cash And Short Term Investments218.7 M146.9 M107.3 M
Slightly volatile
Net Receivables959.2 KM929.5 K
Pretty Stable
Common Stock Total Equity28.2 K47.1 K18.2 K
Slightly volatile
Common Stock Shares Outstanding40.8 M60 M31.6 M
Slightly volatile
Liabilities And Stockholders Equity241.2 M169.9 M119.7 M
Slightly volatile
Non Current Liabilities Total18.9 M18 M5.5 M
Slightly volatile
Capital Surpluse375.5 M678.2 M232.6 M
Slightly volatile
Other Current Assets3.6 M6.6 M2.4 M
Slightly volatile
Other Stockholder Equity490 M844.6 M263.2 M
Slightly volatile
Total Liabilities26.1 M39.3 M14.6 M
Slightly volatile
Property Plant And Equipment Gross14.1 M13.5 M4.4 M
Slightly volatile
Total Current Assets222.7 M154.5 M110.3 M
Slightly volatile
Capital Stock45.3 K47.7 K36.4 M
Slightly volatile
Net Working Capital205.2 M133.2 M100.6 M
Slightly volatile
Common Stock36.3 K61 K20.7 K
Slightly volatile
Property Plant Equipment4.7 M4.5 M1.8 M
Slightly volatile
Short and Long Term Debt Total11.2 M19.5 M7.7 M
Slightly volatile
Non Currrent Assets Other291.7 K307.1 K1.6 M
Slightly volatile
Long Term Debt9.3 M10.9 M7.2 M
Slightly volatile
Long Term Debt Total8.1 M10.8 M7.1 M
Slightly volatile
Non Current Liabilities Other7.5 M7.1 MM
Slightly volatile
Current Deferred Revenue8.4 M9.5 M10.3 M
Slightly volatile
Deferred Long Term Liabilities7.6 M8.6 M9.4 M
Slightly volatile
Short Term Debt1.6 M2.7 M1.1 M
Slightly volatile
Short and Long Term Debt348 K391.5 K427.3 K
Slightly volatile

Alx Oncology Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.1 MM509.8 K
Slightly volatile
Selling General Administrative20.1 M30 M11.7 M
Slightly volatile
Other Operating Expenses95.6 M163.8 M58.5 M
Slightly volatile
Research Development74.4 M133.8 M45.4 M
Slightly volatile
Cost Of Revenue1.3 M784.8 K1.7 M
Slightly volatile
Total Operating Expenses94.4 M163.8 M57.1 M
Slightly volatile
Reconciled Depreciation1.1 MM509.8 K
Slightly volatile
Interest Income11.3 M10.8 M2.8 M
Slightly volatile
Preferred Stock And Other Adjustments4.2 M4.7 M5.1 M
Slightly volatile
Selling And Marketing Expenses668.8 K752.4 K821.2 K
Slightly volatile

Alx Oncology Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation32.7 M31.2 M9.6 M
Slightly volatile
Begin Period Cash Flow24.6 M25.8 M66.8 M
Slightly volatile
Depreciation1.1 MM509.8 K
Slightly volatile
Capital Expenditures488.3 K514 K902 K
Pretty Stable
Total Cash From Financing Activities26.3 M27.7 M37.3 M
Pretty Stable
End Period Cash Flow15.1 M15.9 M58.9 M
Pretty Stable
Change To Netincome28.8 M27.4 M9.2 M
Slightly volatile
Change Receivables428.8 K482.4 K526.5 K
Slightly volatile
Dividends Paid72.1 M68.6 M19 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.7 K2.6 K1.3 K
Slightly volatile
Days Sales Outstanding44.5746.91107
Slightly volatile
Stock Based Compensation To Revenue4.354.141.9246
Slightly volatile
Capex To Depreciation0.440.466.9559
Pretty Stable
EV To Sales2.4 K2.3 K1.2 K
Slightly volatile
Payables Turnover254242110
Slightly volatile
Sales General And Administrative To Revenue11.8411.285.7517
Slightly volatile
Research And Ddevelopement To Revenue23.1522.0512.9517
Slightly volatile
Capex To Revenue0.02870.03020.1828
Slightly volatile
Cash Per Share3.882.22.5317
Slightly volatile
Days Payables Outstanding1.481.5690.6761
Slightly volatile
Income Quality0.911.040.9074
Slightly volatile
Net Debt To EBITDA0.00490.00511.2061
Very volatile
Current Ratio7.938.3510.8023
Pretty Stable
Receivables Turnover4.468.055.0681
Slightly volatile
Capex Per Share0.00940.00990.0294
Very volatile
Revenue Per Share0.03240.03410.0753
Slightly volatile
Interest Debt Per Share0.180.320.2397
Very volatile
Debt To Assets0.170.130.3295
Slightly volatile
Operating Cycle44.5746.91107
Slightly volatile
Days Of Payables Outstanding1.481.5690.6761
Slightly volatile
Ebt Per Ebit1.090.94651.0049
Pretty Stable
Long Term Debt To Capitalization0.0840.08850.6434
Slightly volatile
Total Debt To Capitalization0.290.150.6607
Slightly volatile
Quick Ratio7.938.3510.8023
Pretty Stable
Net Income Per E B T1.11.151.0169
Slightly volatile
Cash Ratio1.041.098.2766
Very volatile
Days Of Sales Outstanding44.5746.91107
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.151.0502
Pretty Stable
Fixed Asset Turnover21.4820.4610.6253
Slightly volatile
Debt Ratio0.170.130.3295
Slightly volatile
Price Sales Ratio2.7 K2.6 K1.3 K
Slightly volatile
Asset Turnover0.0030.00310.1256
Slightly volatile
Gross Profit Margin0.07250.08150.0889
Slightly volatile

Alx Oncology Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap95.2 M100.2 M2.4 B
Slightly volatile
Enterprise Value94.5 M99.5 MB
Slightly volatile

Alx Fundamental Market Drivers

Alx Upcoming Events

14th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Alx Oncology Financial Statements

Alx Oncology investors utilize fundamental indicators, such as revenue or net income, to predict how Alx Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue9.5 M8.4 M
Cost Of Revenue784.8 K1.3 M
Stock Based Compensation To Revenue 4.14  4.35 
Sales General And Administrative To Revenue 11.28  11.84 
Research And Ddevelopement To Revenue 22.05  23.15 
Capex To Revenue 0.03  0.03 
Revenue Per Share 0.03  0.03 
Ebit Per Revenue(42.48)(40.36)

Pair Trading with Alx Oncology

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alx Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alx Oncology will appreciate offsetting losses from the drop in the long position's value.

Moving against Alx Stock

  0.35LION Lionsgate Studios HoldingPairCorr
The ability to find closely correlated positions to Alx Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alx Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alx Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alx Oncology Holdings to buy it.
The correlation of Alx Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alx Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alx Oncology Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alx Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Alx Oncology Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alx Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alx Oncology Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alx Oncology Holdings Stock:
Check out the analysis of Alx Oncology Correlation against competitors.
You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Will Biotechnology sector continue expanding? Could Alx diversify its offerings? Factors like these will boost the valuation of Alx Oncology. If investors know Alx will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Alx Oncology data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(2.01)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.51)
Return On Equity
(1.19)
The market value of Alx Oncology Holdings is measured differently than its book value, which is the value of Alx that is recorded on the company's balance sheet. Investors also form their own opinion of Alx Oncology's value that differs from its market value or its book value, called intrinsic value, which is Alx Oncology's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Alx Oncology's market value can be influenced by many factors that don't directly affect Alx Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Alx Oncology's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Alx Oncology represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Alx Oncology's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.